Format

Send to

Choose Destination
Rev Med Interne. 2016 Apr;37(4):274-8. doi: 10.1016/j.revmed.2015.08.012. Epub 2015 Sep 14.

Biotherapies in large vessel vasculitis.

Author information

1
Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
2
Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Viale Risorgimento, 80, 42123 Reggio Emilia, Italy. Electronic address: salvarani.carlo@asmn.re.it.

Abstract

The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

KEYWORDS:

Biological therapies; Biotherapies; Giant cell arteritis; Large vessel vasculitis; Takayasu arteritis

PMID:
26383765
DOI:
10.1016/j.revmed.2015.08.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center